Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have demonstrated the potential for a new combination therapy to improve outcomes for patients with ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

They found no direct genetic explanation, but they did find a statistically significant enrichment of genes that are subject to regulatory control of the JAK-STAT signalling pathway among genes whose ...

Piper Sandler lowered the firm’s price target on Karyopharm (KPTI) to split-adjusted $15 from $75 and keeps an Overweight rating on the shares ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here ...

The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

Why do medications that are supposed to help patients with chronic inflammatory diseases sometimes lead to blood clots?